This narrative state-of-the-art review paper describes the progress in the understanding and
treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Synaptic loss and deficits in functional connectivity are hypothesized to contribute to
symptoms associated with major depressive disorder (MDD) and post-traumatic stress …

Recent scientific and technological advances have brought us closer to being able to apply
a true biopsychosocial approach to the study of resilience in humans. Decades of research …

Current medication for anxiety disorders is suboptimal in terms of efficiency and tolerability,
highlighting the need for improved drug treatments. In this review an overview of drugs …

Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Over the past 50 years, ketamine has solidified its position in both human and veterinary
medicine as an important anesthetic with many uses. More recently, ketamine has been …

Background The glutamatergic modulator ketamine has created a blueprint for studying
novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic …

Quantifying neural activity in natural conditions (ie conditions comparable to the standard
clinical patient experience) during the administration of psychedelics may further our …